Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Gitlin

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Menopause (New York, N.Y.)|September 20, 2011
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research DatabaseLin Li, Andrew Roddam, Matthew Gitlin, et al.
BMC Nephrology|October 11, 2013
An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survivalJuan C Scornik, Jonathan S Bromberg, Douglas J Norman, et al.
Journal of Medical Economics|November 26, 2011
Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysisHuseyin Naci, Gregory de Lissovoy, Christopher Hollenbeak, et al.
BMC Nephrology|July 13, 2014
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labelsKatherine A Cappell, Sanatan Shreay, Zhun Cao, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2014
Evaluation of the consumer assessment of healthcare providers and systems in-center hemodialysis surveyRobert Wood, Carly J Paoli, Ron D Hays, et al.
Plastic and Reconstructive Surgery. Global Open|September 14, 2016
The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast SurgeryScott L Spear, Courtney N Coles, Braden K Leung, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|May 17, 2007
The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectivesHilary H Colwell, Susan D Mathias, Nita H Ngo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 6, 2010
Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agentsKirsten L Johansen, Fredric O Finkelstein, Dennis A Revicki, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 10, 2013
Clinical factors and the decision to transfuse chronic dialysis patientsCynthia B Whitman, Sanatan Shreay, Matthew Gitlin, et al.
Transplantation and Cellular Therapy|June 26, 2023
Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation PatientRichard T Maziarz, Steven Devine, Louis P Garrison, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Menopause (New York, N.Y.)|September 20, 2011
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research DatabaseLin Li, Andrew Roddam, Matthew Gitlin, et al.
BMC Nephrology|October 11, 2013
An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survivalJuan C Scornik, Jonathan S Bromberg, Douglas J Norman, et al.
Journal of Medical Economics|November 26, 2011
Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysisHuseyin Naci, Gregory de Lissovoy, Christopher Hollenbeak, et al.
BMC Nephrology|July 13, 2014
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labelsKatherine A Cappell, Sanatan Shreay, Zhun Cao, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2014
Evaluation of the consumer assessment of healthcare providers and systems in-center hemodialysis surveyRobert Wood, Carly J Paoli, Ron D Hays, et al.
Plastic and Reconstructive Surgery. Global Open|September 14, 2016
The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast SurgeryScott L Spear, Courtney N Coles, Braden K Leung, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|May 17, 2007
The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectivesHilary H Colwell, Susan D Mathias, Nita H Ngo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 6, 2010
Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agentsKirsten L Johansen, Fredric O Finkelstein, Dennis A Revicki, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 10, 2013
Clinical factors and the decision to transfuse chronic dialysis patientsCynthia B Whitman, Sanatan Shreay, Matthew Gitlin, et al.
Transplantation and Cellular Therapy|June 26, 2023
Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation PatientRichard T Maziarz, Steven Devine, Louis P Garrison, et al.
Pageof 6